These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18004211)

  • 21. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
    Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
    Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
    Liu W; Liu K; Wood HB; McCann ME; Doebber TW; Chang CH; Akiyama TE; Einstein M; Berger JP; Meinke PT
    J Med Chem; 2009 Jul; 52(14):4443-53. PubMed ID: 19530681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias.
    Yong EL; Li J; Liu MH
    Curr Opin Lipidol; 2008 Apr; 19(2):106-12. PubMed ID: 18388689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
    Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
    Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients.
    Mtiraoui N; Ezzidi I; Kacem M; Ben Hadj Mohamed M; Chaieb M; Haj Jilani AB; Mahjoub T; Almawi WY
    Diabetes Metab Res Rev; 2009 Jan; 25(1):57-63. PubMed ID: 19031431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
    Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
    Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening.
    Nair S; Phillips AO; Norton N; Spurlock G; Williams HJ; Craig KJ; Williams JD; Williams NM; Bowen T
    J Nephrol; 2008; 21(3):400-5. PubMed ID: 18587729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy.
    Szeto CC; Chow KM; Poon PY; Kwan BC; Li PK
    Am J Nephrol; 2008; 28(5):715-22. PubMed ID: 18417957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes.
    Magae J; Tsuruga M; Maruyama A; Furukawa C; Kojima S; Shimizu H; Ando K
    J Antibiot (Tokyo); 2009 Jul; 62(7):365-9. PubMed ID: 19557028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.
    Kühne A; Kaiser R; Schirmer M; Heider U; Muhlke S; Niere W; Overbeck T; Hohloch K; Trümper L; Sezer O; Brockmöller J
    Pharmacogenet Genomics; 2007 Jul; 17(7):505-17. PubMed ID: 17558306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-crystal structure guided array synthesis of PPARgamma inverse agonists.
    Trump RP; Cobb JE; Shearer BG; Lambert MH; Nolte RT; Willson TM; Buckholz RG; Zhao SM; Leesnitzer LM; Iannone MA; Pearce KH; Billin AN; Hoekstra WJ
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3916-20. PubMed ID: 17533125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPARgamma agonists: safety issues in heart failure.
    Tang WH; Maroo A
    Diabetes Obes Metab; 2007 Jul; 9(4):447-54. PubMed ID: 17587386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response.
    Adamo KB; Dent R; Langefeld CD; Cox M; Williams K; Carrick KM; Stuart JS; Sundseth SS; Harper ME; McPherson R; Tesson F
    Obesity (Silver Spring); 2007 May; 15(5):1068-75. PubMed ID: 17495181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of oedema in nephrotic syndrome: role of epithelial sodium channel.
    Kim SW; Frøkiaer J; Nielsen S
    Nephrology (Carlton); 2007 Dec; 12 Suppl 3():S8-10. PubMed ID: 17995529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic contributions to type 2 diabetes: recent insights.
    Sale MM; Rich SS
    Expert Rev Mol Diagn; 2007 Mar; 7(2):207-17. PubMed ID: 17331067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel epithelial sodium channel gamma-subunit de novo frameshift mutation leads to Liddle syndrome.
    Wang Y; Zheng Y; Chen J; Wu H; Zheng D; Hui R
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):801-4. PubMed ID: 17634077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel.
    Nofziger C; Chen L; Shane MA; Smith CD; Brown KK; Blazer-Yost BL
    Pflugers Arch; 2005 Dec; 451(3):445-53. PubMed ID: 16170524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MCC-555 (Mitsubishi-Tokyo Pharmaceuticals).
    Velussi M
    IDrugs; 2001 May; 4(5):586-9. PubMed ID: 16012905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.